Verve Therapeutics Inc.

In News

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data - insights.citeline.com

insights.citeline.com - May 26, 2026

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - Eli Lilly

Eli Lilly - Jun 17, 2025

Lilly to acquire Verve Therapeutics for $1.3 billion - Chemical & Engineering News

Chemical & Engineering News - Jun 18, 2025

Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com

drugdiscoverytrends.com - Jul 19, 2025

Verve Therapeutics Acquired by Eli Lilly in $1 Billion Deal - Paul, Weiss

Paul, Weiss - Jul 25, 2025

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Yahoo Finance - Apr 01, 2025

Lilly and Verve announce expiration of Verve tender offer - PR Newswire

PR Newswire - Jul 24, 2025

Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire

GlobeNewswire - Apr 14, 2025

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - WSJ

WSJ - Jun 17, 2025

Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio - Seeking Alpha

Seeking Alpha - Aug 30, 2024

Verve’s second swing at gene editing for heart disease shows early promise - BioPharma Dive

BioPharma Dive - Apr 14, 2025

Lilly beams up Verve gene therapy programs for $600M from deal-hungry Beam - Fierce Biotech

Fierce Biotech - Oct 31, 2023

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment